Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Opioid REMS Meeting Nears, FDA Notes Worry About Shifting Use To Different Class

This article was originally published in The Pink Sheet Daily

Executive Summary

In NEJM editorial, FDA's Woodcock suggests "unintended consequences" of any risk management plan for the pain products.

You may also be interested in...



Pain Market Draws New NDA Submissions

Pharma giant J&J and specialty drug company Javelin Pharmaceuticals are both seeking NDAs for new formulations of already approved pain medications.

Pain Market Draws New NDA Submissions

Pharma giant J&J and specialty drug company Javelin Pharmaceuticals are both seeking NDAs for new formulations of already approved pain medications.

Reopening Of Public Comment Period For Opioid Class REMS Confirms Long Road Ahead

FDA is reopening the public comment period for the class-wide opioid Risk Evaluation and Mitigation Strategy until Oct. 19, 2010.

Related Content

Topics

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel